The company plans to submit a Biologics Licence Application to the US Food and Drug Administration later in 2025 for its DMD ...

Orca Bio’s T-cell immunotherapy candidate for blood cancers has more than doubled the number of patients surviving free of ...

The FDA has removed the clinical hold on vTv Therapeutics' cadisegliatin clinical programme, including the Phase III CATT1 trial for T1D.

Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.

AstraZeneca acquired the hypoparathyroidism therapy eneboparatide as part of a buyout of Amolyt Pharma in July 2024.

Anocca has secured authorisation from regulatory authorities in four European nations for its Phase I/II VIDAR-1 clinical ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

The United States is experiencing a multi-state measles outbreak, resulting in the highest case spike since 2019.

AbbVie has reported analysis from a Phase III trial that assessed Elahere against chemotherapy for platinum-resistant ovarian ...

The Phase I/II trial sought to establish the impact of DYNE-251 on mobility-related endpoints, seeing an increase over ...

The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.

Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAb in their systems.